BURLINGTON, Mass. - scPharmaceuticals Inc. (NASDAQ: NASDAQ:SCPH), a pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved the expansion of the indication for FUROSCIX to include treatment for all classes of chronic heart failure patients.
This approval extends the use of FUROSCIX, previously limited to New York Heart Association (NYHA) Class II and III patients, to those with NYHA Class IV chronic heart failure, who experience the most severe symptoms and limitations.
FUROSCIX is a subcutaneous formulation of furosemide, a diuretic commonly used to reduce fluid overload in heart failure patients. The approval is based on demonstrated efficacy and safety in treating congestion due to fluid overload, which could potentially prevent hospital admissions or readmissions related to heart failure.
John Tucker, CEO of scPharmaceuticals, stated that the FDA's decision is a "natural expansion" of the drug's indication, given its established benefits. The company anticipates that this approval will contribute to sustained long-term growth, supported by increasing adoption by cardiologists and heart failure specialists.
The FDA's approval is particularly significant for the approximately 10% of heart failure patients nationally who are classified as NYHA Class IV. These patients suffer from the most debilitating symptoms, severely limiting their physical activity.
In clinical trials, the most common adverse reactions to FUROSCIX were skin reactions at the site of administration, including erythema, bruising, edema, and pain. The medication is contraindicated in patients with conditions such as anuria, hypersensitivity to furosemide, certain components of the formulation or medical adhesives, and hepatic cirrhosis.
scPharmaceuticals, headquartered in Burlington (NYSE:BURL), Massachusetts, is focused on developing products aimed at reducing healthcare costs and improving patient outcomes. The company's portfolio primarily targets the outpatient care of acute conditions through subcutaneous administration of IV-strength treatments.
The information in this article is based on a press release statement from scPharmaceuticals.
In other recent news, scPharmaceuticals Inc. announced its plan for a public offering of its common stock, managed by Leerink Partners and TD Cowen, subject to market conditions and other factors.
The company also disclosed its Q1 2024 financials, reporting a net revenue of $6.1 million and a net loss of $14.1 million, with cash and cash equivalents of $58.4 million. Despite a cyber-attack resulting in a 10% loss of doses, scPharmaceuticals has maintained momentum with strategic initiatives, including the expansion of its FUROSCIX product indications.
The company has also announced that the FDA has accepted its sNDA for the FUROSCIX drug expansion, aiming to treat edema due to fluid overload in patients with chronic kidney disease. This potential expansion targets a $3 billion market.
scPharmaceuticals is in ongoing discussions with payers for FUROSCIX and is planning for long-term growth initiatives, including potential expansion of FUROSCIX indication for Class 4 heart failure and CKD patients. Despite increased costs across product revenues, R&D, and administrative expenses, the company is moving forward with plans to expand territories and educate physicians on new FUROSCIX indications.
InvestingPro Insights
Following the FDA's approval for the expanded use of FUROSCIX, scPharmaceuticals Inc. (NASDAQ: SCPH) is poised to make significant strides in the heart failure treatment market. With analysts anticipating sales growth in the current year, the company's strategic focus on outpatient care for acute conditions may be well-timed. This is underscored by the fact that scPharmaceuticals holds more cash than debt on its balance sheet, indicating a solid financial position to support its operational and strategic initiatives.
Despite the optimism surrounding sales growth, it's important to note that the company has not been profitable over the last twelve months, and analysts do not expect it to be profitable this year. This is reflected in the company's negative P/E ratio of -2.71. The high Price / Book multiple of 6.35 also suggests that the market values the company's assets quite generously relative to its book value, which could be attributed to the potential market opportunity for FUROSCIX following the FDA's approval.
Investors should consider that scPharmaceuticals is quickly burning through cash, which may warrant close monitoring of their financial health moving forward. However, their liquid assets exceed short-term obligations, providing some cushion for near-term financial challenges. For those interested in a deeper dive, InvestingPro offers additional tips on scPharmaceuticals, including detailed financial metrics and analyst forecasts, available at https://www.investing.com/pro/SCPH.
It's also worth mentioning that scPharmaceuticals does not pay a dividend to shareholders, which could influence investment decisions for income-focused investors. Nevertheless, the company's recent FDA approval could be a catalyst for growth as it potentially expands its market reach to a broader patient population with chronic heart failure.
For investors seeking a more comprehensive analysis, there are further InvestingPro Tips on scPharmaceuticals, totaling seven in number, which can provide more nuanced insights into the company's financial standing and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.